Treatment for Early Memory Loss
Cognition Disorders, Alzheimer Disease
About this trial
This is an interventional treatment trial for Cognition Disorders focused on measuring Cognition, Memory
Eligibility Criteria
Inclusion Criteria: Display impairment on at least 2 of 3 memory tests Meet the following criteria for mild cognitive impairment: subjective complaint of memory problems; no impairment in activities of daily living; general cognitive function in the normal age-adjusted range; abnormal memory function for age; and lacking full DSM criteria for dementia Exclusion Criteria: Have a history of major neurological, metabolic, psychiatric or cardiovascular disease (patients with a history of non-CNS oncologic disease treated surgically and currently in remission will not be excluded) Have a cerebrovascular condition Abuse alcohol or drugs Have renal or hepatic disease, diabetes mellitus, gout, or adrenocortical insufficiency Are sensitive to carbonic anhydrase inhibitors, antibacterial sulfonamides, thiazide diuretics, or other sulfonamide-derivative diuretics Have taken donepezil or GBE products prior to enrollment Have taken medications, including herbal agents (exceptions will be made for routine health maintenance medications such as alendronate [Fosamax] for osteoporosis, vitamin therapy [not to exceed 200 percent RDA for any particular vitamin], thyroid replacement therapy, hormone replacement, and ophthalmic medications for glaucoma and other eye disorders)
Sites / Locations
- University of Iowa Department of Psychiatry